Aldeyra slides as lead drug flunks a pri­ma­ry end­point in PhI­Ib

First things first.

Aldeyra’s Phase IIb study for its lead eye drug ADX-102 failed the pri­ma­ry end­point in treat­ing al­ler­gic con­junc­tivi­tis. And if you dig a bit you can find that in its state­ment to­day, not­ing that a one-point dif­fer­en­ti­a­tion from place­bo at the 5-minute time point spec­i­fied for gaug­ing the im­pact on oc­u­lar itch­ing didn’t qual­i­fy for suc­cess.

But in­ves­ti­ga­tors for the Lex­ing­ton, MA-based biotech spent much more time fo­cus­ing on the pos­i­tive. Specif­i­cal­ly, the da­ta did ap­proach the thresh­old of sta­tis­ti­cal sig­nif­i­cance, re­searchers say, and if you looked at a va­ri­ety of time points af­ter an al­ler­gen chal­lenge — demon­strat­ing “a nov­el ac­tiv­i­ty pro­file that ad­dress­es late phase in­flam­ma­tion gen­er­al­ly not af­fect­ed by an­ti­his­t­a­mines” — there was a sig­nif­i­cant ben­e­fit for pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER